Loading this company
Revvity, Inc.
RVTYPrices in USD
TickerWorth ScoreD45/100
What we think
Priced above our range of $15.90 to $124.33.
Price
$153.53USD up +$0.89 (+0.58%)
Quoted · Prices are delayed.
Showing the last price we hold for this listing, recorded 2026-10-19 15:44 UTC (7 hours ago).
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 3 models, on today’s numbers
$15.90–$124.33
What the price needs: revenue growth of more than 25%/yr for 5 years (our model assumes 3.1%), or investors accepting a ~4.0% discount rate, vs the 9.6% our model uses.
Led by discounted cash flow (DCF) · Steady cash-flow business
Price $153.53Priced · Prices are delayed.
Is it a good business?
- Valuation50 out of 100
- Growth67 out of 100
- Financial health67 out of 100
- Dividend75 out of 100
- Past performance83 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$147.53 across 15 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Revvity, Inc. provides health sciences solutions, technologies, and services. It operates in the Diagnostics & Research industry (Healthcare sector), headquartered in United States. The company employs roughly 11,000 people.
Revenue: Product 84% · Service 16%
Key stats
52-week range$81.22–$166.25
- Open
- $153.89
- Day high
- $156.87
- Day low
- $153.13
- Previous close
- $152.64
- Volume
- 258,362 · 0.14× avg
- Average volume
- 1,837,798
- Market cap
- $17,131,859,968.00
- P/E (TTM)
- 73.46
- Earnings per share
- $2.09
- Beta
- 1.06
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Reported quarterly or annual results
- Reported quarterly or annual results
- Amended its charter or bylaws
- Reported quarterly or annual results
- Reported quarterly or annual results
- Reported quarterly or annual results
- Changed leadership or its board
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Gonzales AnitaOpen-market sale · $13,060.32
- Krakowiak MaxwellOpen-market sale ·
Not investment advice. TickerWorth Score is a model output.